GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
| Autor: | Tao Schechter, Christina Peters, Jean-Hugues Dalle, Saba Azarnoush, Yves Théorêt, Yves Chalandon, Petr Sedlacek, Imke H. Bartelink, Tiago Nava, Jaap Jan Boelens, Laurence Lesne, Victor Lewis, M A Rezgui, Patricia Huezo-Diaz Curtis, Marc Ansari, Henrique Bittencourt, Robbert G. M. Bredius, Martin A. Champagne, L. Lee Dupuis, Chakradhara Rao S. Uppugunduri, Maja Krajinovic, Vid Mlakar |
|---|---|
| Přispěvatelé: | Clinical pharmacology and pharmacy |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Pediatrics medicine.medical_treatment Population Hematopoietic stem cell transplantation hematopoietic stem cell transplantion 03 medical and health sciences 0302 clinical medicine Internal medicine Acute graft versus host disease medicine busulfan education pharmacogenetics education.field_of_study ddc:618 Hematology business.industry toxicity 3. Good health Transplantation 030104 developmental biology Multicenter study Oncology 030220 oncology & carcinogenesis Toxicity business pharmacokinetics Busulfan Research Paper medicine.drug |
| Zdroj: | Oncotarget, 8(53), 90852. Impact Journals Oncotarget, 8(53), 90852-90867 Oncotarget Ansari, M, Curtis, P H D, Uppugunduri, C R S, Rezgui, M A, Nava, T, Mlakar, V, Lesne, L, Théoret, Y, Chalandon, Y, Dupuis, L L, Schechter, T, Bartelink, I H, Boelens, J J, Bredius, R, Dalle, J H, Azarnoush, S, Sedlacek, P, Lewis, V, Champagne, M, Peters, C, Bittencourt, H & Krajinovic, M 2017, ' GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation : A multicenter study ', Oncotarget, vol. 8, no. 53, pp. 90852-90867 . https://doi.org/10.18632/oncotarget.20310 Oncotarget, Vol. 8, No 53 (2017) pp. 90852-90867 Oncotarget, 8(53), 90852-90867. Impact Journals |
| ISSN: | 0125-7854 1949-2553 |
| Popis: | // Marc Ansari 1,2 , Patricia Huezo-Diaz Curtis 1,2,* , Chakradhara Rao S. Uppugunduri 1,2,* , Mohammed Aziz Rezgui 3 , Tiago Nava 1,3,5,6 , Vid Mlakar 1,2 , Laurence Lesne 1,2 , Yves Theoret 3,4,5 , Yves Chalandon 7 , Lee L. Dupuis 8 , Tao Schechter 8 , Imke H. Bartelink 9,17 , Jaap J. Boelens 9 , Robbert Bredius 10 , Jean-Hugues Dalle 11 , Saba Azarnoush 11 , Petr Sedlacek 12 , Victor Lewis 13 , Martin Champagne 14 , Christina Peters 15 , Henrique Bittencourt 3,4,5,16 and Maja Krajinovic 3 - 5,16,18 1 Department of Pediatrics, CANSEARCH Research Laboratory, Faculty of Medicine, Geneva, Switzerland 2 Department of Pediatrics, Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland 3 Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, Quebec, Canada 4 Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada 5 Clinical Pharmacology Unit, CHU Sainte-Justine, Montreal, Quebec, Canada 6 Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil 7 Department of Medical Specialties, Division of Hematology, Geneva University Hospital, Geneva, Switzerland 8 Department of Haematology/Oncology, Blood and Marrow Transplant Unit, The Hospital for Sick Children, Toronto, Ontario, Canada 9 Pediatric Blood and Marrow Transplantation Program, University Medical Center, Utrecht, The Netherlands 10 Department of Pediatrics, Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 11 Pediatric Hematology Department, Robert Debre Hospital, Assistance Publique, Hopitaux de Paris, Paris, France 12 Department of Pediatric Hematology and Oncology Teaching Hospital, 2nd Medical School, Charles University, Prague, Czech Republic 13 Department of Pediatrics, Alberta Children’s Hospital, Calgary, Alberta, Canada 14 Department of Hematology, Hospital Verdun, Montreal, Quebec, Canada 15 Department of Pediatrics, Stem Cell Transplantation Unit, St Anna Children’s Hospital, Vienna, Austria 16 Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada 17 Department of Medicine, The University of California San Francisco, San Francisco, CA, USA 18 On Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, Leiden, The Netherlands * These authors have contributed equally to this work Correspondence to: Patricia Huezo-Diaz Curtis, email: // Keywords : busulfan, pharmacokinetics, pharmacogenetics, toxicity, hematopoietic stem cell transplantion Received : July 18, 2017 Accepted : July 23, 2017 Published : August 27, 2017 Abstract Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of hematopoietic stem cell transplantation (HSCT). Further improvement could be achieved through genotype-guided BU dose adjustments. To investigate this aspect, polymorphism within glutathione S transferase genes were assessed. Particularly, promoter haplotypes of the glutathione S transferase A1 ( GSTA1 ) were evaluated in vitro, with reporter gene assays and clinically, in a pediatric multi-center study (N =138) through association with BU pharmacokinetics (PK) and clinical outcomes. Promoter activity significantly differed between the GSTA1 haplotypes (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|